# Role of Alpha-Synuclein in Frontotemporal Dementia: Narrative Review

## TL;DR

Alpha-synuclein worsens frontotemporal dementia by combining with other proteins, leading to faster brain cell loss and worse outcomes.

## Contribution

Highlights alpha-synuclein's role in accelerating FTD through cross-seeding with Tau and TDP-43, calling for multi-target therapies.

## Key findings

- Alpha-synuclein cross-seeds with Tau and TDP-43, speeding up neurotoxicity and neuronal loss in FTD.
- Secondary alpha-synuclein pathology is linked to poor prognosis, rapid cognitive decline, and shorter survival.
- Current biomarkers often miss alpha-synuclein co-pathology, potentially reducing the effectiveness of clinical trials.

## Abstract

What are the main findings?
Alpha-synuclein cross-seeds with Tau and TDP-43, accelerating neurotoxicity and neuronal loss in FTD.Secondary alpha-synuclein pathology predicts poor prognosis, rapid executive decline, and shorter survival times.

Alpha-synuclein cross-seeds with Tau and TDP-43, accelerating neurotoxicity and neuronal loss in FTD.

Secondary alpha-synuclein pathology predicts poor prognosis, rapid executive decline, and shorter survival times.

What are the implications of the main findings?
Undetected alpha-synuclein may obscure potential trial benefits, necessitating biomarker screening for accurate patient stratification.Future therapies must adopt multi-target cocktail approaches to neutralize synergistic protein toxicity simultaneously.

Undetected alpha-synuclein may obscure potential trial benefits, necessitating biomarker screening for accurate patient stratification.

Future therapies must adopt multi-target cocktail approaches to neutralize synergistic protein toxicity simultaneously.

Background: Frontotemporal dementia (FTD) is traditionally classified based on the accumulation of either tau or TDP-43 proteins; however, the presence of alpha-synuclein (α-Syn) in these patients is increasingly recognized as a critical factor driving disease progression. Methods: A comprehensive narrative review of recent clinical, neuropathological, and biochemical studies was conducted, focusing on cases of FTLD-synuclein and the occurrence of alpha-syn as a co-pathology in more common FTD variants. Results: Current evidence indicates that α-syn often co-aggregates with tau and TDP-43 via “cross-seeding” mechanisms, significantly accelerating neuronal loss and contributing to clinical heterogeneity. Although FTLD-synuclein is a rare, distinct subtype that mimics atypical multiple system atrophy, secondary α-syn pathology is common and strongly correlates with rapid cognitive decline. Furthermore, existing diagnostic biomarkers typically fail to detect this pathological overlap, which may explain the limited efficacy in protein-specific clinical trials. Conclusions: α-Syn is a major, yet under-recognized, catalyst of neurodegeneration within the FTD spectrum. The findings emphasize the need for future therapeutic and diagnostic strategies to adopt multi-target approaches, addressing the synergistic toxicity of multiple protein aggregates rather than isolating single protein in isolation.